Immunex

(IMNX)

received

Food and Drug Administration

approval to market

Novantrone

TST Recommends

as a treatment for certain forms of multiple sclerosis.

Novantrone is currently marketed, in combination with corticosteroids, to treat pain in patients with advanced hormone-refractory prostate cancer and for an initial therapy of acute nonlymphocytic leukemia.

The FDA approval allows Immunex to promote Novantrone as a treatment for secondary progressive multiple sclerosis.

Shares of Immunex recently traded up $1.25, or 3.3%, to $38.88 in

Nasdaq

in midday trading.